Apogee strengthens case for longer-lasting eczema drug
BioPharma Dive
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.
pharminent
March 23, 2026 (Last updated: March 24, 2026)
BioPharma Dive
Company shares climbed by more than 20% on Phase 2 study results suggesting the therapy could provide sustained relief when administered once every three or six months.
